post conference buying from u.s.?, page-8

PoS the NPV valuation is US$250m just for the US market alone. This is just for TBI not stroke. The global market would be massive. As you say, they already know alot ie toxicity and that it is safe for women and can be taken orally. If you read the first few slides of the US Army presentation about the pre-clinical trial results it reads very well. This is definitely an undervalued company. It is risky selling out on rallies as it is probably just a matter of time before a tsunami of buying lifts NEU skyward. I remember in 2003 when Paladin (PDN) was unloved at 1.6c then there were some strong broker reports and investor newsletters from the US and the buyers just absolutely swamped them and they rose to $10 per share.